Ortho Clinical Diagnostics, a leading player in the in vitro diagnostics industry, is headquartered in the United States. Founded in 1939, the company has established itself as a pioneer in blood testing and transfusion diagnostics, serving healthcare providers across the globe. With a strong presence in North America, Europe, and Asia, Ortho Clinical Diagnostics focuses on delivering innovative solutions that enhance laboratory efficiency and patient care. The company’s core offerings include advanced blood screening, clinical chemistry, and immunoassay systems, distinguished by their accuracy and reliability. Notable achievements include the development of the first FDA-approved blood screening test for HIV. With a commitment to quality and innovation, Ortho Clinical Diagnostics continues to solidify its market position as a trusted partner in the healthcare sector, driving advancements in diagnostic technology.
How does Ortho Clinical Diagnostics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ortho Clinical Diagnostics's score of 20 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Ortho Clinical Diagnostics reported total greenhouse gas emissions of approximately 26,371,000 kg CO2e for Scope 1 and 28,869,000 kg CO2e for Scope 2, resulting in a combined total of about 55,240,000 kg CO2e. This marked a slight increase in emissions compared to 2021, where they recorded approximately 17,320,000 kg CO2e for Scope 1 and 27,971,000 kg CO2e for Scope 2, totalling around 45,291,000 kg CO2e. In 2020, the company reported approximately 19,409,000 kg CO2e for Scope 1 and 26,398,000 kg CO2e for Scope 2, leading to a total of about 45,807,000 kg CO2e. The emissions data indicates a trend of fluctuating emissions over the years, with a notable increase in 2022. Ortho Clinical Diagnostics has not disclosed specific reduction targets or initiatives related to their carbon emissions, nor have they committed to Science Based Targets Initiative (SBTi) reduction targets. The absence of defined climate pledges suggests a need for further commitment to sustainability practices within the industry context. Overall, while Ortho Clinical Diagnostics has made strides in tracking their emissions, the lack of clear reduction strategies highlights an opportunity for enhanced climate action moving forward.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | |
---|---|---|---|
Scope 1 | 19,409,000 | 00,000,000 | 00,000,000 |
Scope 2 | 26,398,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ortho Clinical Diagnostics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.